Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (PROMISE-AF)

Trial Profile

A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (PROMISE-AF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs OMT 28 (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms PROMISE-AF
  • Sponsors OMEICOS Therapeutics
  • Most Recent Events

    • 10 Jan 2019 Status changed from planning to recruiting.
    • 15 Nov 2018 New trial record
    • 02 Nov 2018 According to an OMEICOS Therapeutics media release, the company announced the closing of a USD 19.5 million Series C financing led by new investor Forbion. The proceeds from this will be utilized for conduct of this trial and development of companies pipeline.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top